Medicure Inc. (CVE:MPH – Get Free Report) shares reached a new 52-week high during trading on Monday. The company traded as high as C$2.92 and last traded at C$2.93, with a volume of 705 shares changing hands. The stock had previously closed at C$2.88.
Medicure Price Performance
The stock has a market capitalization of C$30.58 million, a PE ratio of -4.07 and a beta of 0.98. The company’s 50 day simple moving average is C$2.00 and its 200 day simple moving average is C$1.44. The company has a current ratio of 0.97, a quick ratio of 1.28 and a debt-to-equity ratio of 6.02.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Read More
- Five stocks we like better than Medicure
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
